Betulinic acid for cancer treatment and prevention

International Journal of Molecular Sciences

Volumn 9, Issue 6, 2008, Pages 1096-1107

  Fulda, Simone ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Betulinic acid; Cancer; Mitochondria

Indexed keywords

20,29 DIHYDRO BETULINIC ACID DERIVATIVE; 23 HYDROXY BETULINIC ACID; ANTINEOPLASTIC AGENT; BETULIC ACID; BETULINIC ACID DERIVATIVE; BEVIRIMAT; CASPASE 8; DOXORUBICIN; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROSOMAL AMINOPEPTIDASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BARK; CANCER CELL; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DYSPLASTIC NEVUS; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG METASTASIS; MELANOMA; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; TREATMENT FAILURE;

EID: 46749135974     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms9061096     Document Type: Review

References (56)

1. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 2003, 66, 1022-1037.
2. Evan, G. I.; Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411, 342-348.
3. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
4. Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25, 4812-4830.
5. Cichewicz, R. H.; Kouzi, S. A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. 2004, 24, 90-114.
6. Alakurtti, S.; Makela, T.; Koskimies, S.; Yli-Kauhaluoma, J. Pharmacological properties of the ubiquitous natural product betulin. Eur. J. Pharm. Sci. 2006, 29, 1-13.
7. Green, D. R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305, 626-629.
8. Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25, 4812-4830.
9. Fulda, S.; Scaffidi, C.; Susin, S. A.; Krammer, P. H.; Kroemer, G.; Peter, M. E.; Debatin, K. M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 1998, 273, 33942-33948.
10. Andre, N.; Carre, M.; Brasseur, G.; Pourroy, B.; Kovacic, H.; Briand, C.; Braguer, D. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 2002, 532, 256-260.
11. Fulda, S.; Susin, S. A.; Kroemer, G.; Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 1998, 58, 4453-4460.
12. Wick, W.; Grimmel, C.; Wagenknecht, B.; Dichgans, J.; Weller, M. Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J. Pharmacol. Exp. Ther. 1999, 289, 1306-1312.
13. Tan, Y.; Yu, R.; Pezzuto, J. M. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin. Cancer Res. 2003, 9, 2866-2875.
14. Fulda, S.; Friesen, C.; Los, M.; Scaffidi, C.; Mier, W.; Benedict, M.; Nunez, G.; Krammer, P. H.; Peter, M. E.; Debatin, K. M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 1997, 57, 4956-4964.
15. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26, 1324-1337.
16. Selzer, E.; Pimentel, E.; Wacheck, V.; Schlegel, W.; Pehamberger, H.; Jansen, B.; Kodym, R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Invest. Dermatol. 2000, 114, 935-940.
17. Selzer, E.; Thallinger, C.; Hoeller, C.; Oberkleiner, P.; Wacheck, V.; Pehamberger, H.; Jansen, B. Betulinic acid-induced Mcl-1 expression in human melanoma--mode of action and functional significance. Mol. Med. 2002, 8, 877-884.
18. Thurnher, D.; Turhani, D.; Pelzmann, M.; Wannemacher, B.; Knerer, B.; Formanek, M.; Wacheck, V.; Selzer, E. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 2003, 25, 732-740.
19. Fulda, S.; Debatin, K. M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med. Pediatr. Oncol. 2000, 35, 616-618.
20. Meng, R. D.; El-Deiry, W. S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp. Cell Res. 2001, 262, 154-169.
21. Salti, G. I.; Kichina, J. V.; Das Gupta, T. K.; Uddin, S.; Bratescu, L.; Pezzuto, J. M.; Mehta, R. G.; Constantinou, A. I. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. Melanoma Res. 2001, 11, 99-104.
22. Zuco, V.; Supino, R.; Righetti, S. C.; Cleris, L.; Marchesi, E.; Gambacorti-Passerini, C.; Formelli, F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002, 175, 17-25.
23. Ehrhardt, H.; Fulda, S.; Fuhrer, M.; Debatin, K. M.; Jeremias, I. Betulinic acid-induced apoptosis in leukemia cells. Leukemia 2004, 18, 1406-1412.
24. Kasperczyk, H.; La Ferla-Bruhl, K.; Westhoff, M. A.; Behrend, L.; Zwacka, R. M.; Debatin, K. M.; Fulda, S. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 2005, 24, 6945-6956.
25. Takada, Y.; Aggarwal, B. B. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J. Immunol. 2003, 171, 3278-3286.
26. Kwon, H. J.; Shim, J. S.; Kim, J. H.; Cho, H. Y.; Yum, Y. N.; Kim, S. H.; Yu, J. Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells. Jpn. J. Cancer Res. 2002, 93, 417-425.
27. Melzig, M. F.; Bormann, H. Betulinic acid inhibits aminopeptidase N activity. Planta Med. 1998, 64, 655-657.
28. Sjostrom, H.; Noren, O.; Olsen, J. Structure and function of aminopeptidase N. Adv. Exp. Med. Biol. 2000, 477, 25-34.
29. Chintharlapalli, S.; Papineni, S.; Ramaiah, S. K.; Safe, S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 2007, 67, 2816-2823.
30. Mukherjee, R.; Jaggi, M.; Rajendran, P.; Srivastava, S. K.; Siddiqui, M. J. A.; Vardhan, A.; Burman, A. C. Synthesis of 3-O-acyl/3-benzylidene/3- hydrazone/3-hydrazine/17-carboxyacryloyl ester derivatives of betulinic acid as anti-angiogenic agents. Bioorg. Med. Chem. Lett. 2004, 14, 3169-3172.
31. Chowdhury, A. R.; Mandal, S.; Mittra, B.; Sharma, S.; Mukhopadhyay, S.; Majumder, H. K. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med. Sci. Monit. 2002, 8, BR254-265.
32. Rieber, M.; Strasberg Rieber, M. Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma. DNA Cell Biol. 1998, 17, 399-406.
33. Pisha, E.; Chai, H.; Lee, I. S.; Chagwedera, T. E.; Farnsworth, N. R.; Cordell, G. A.; Beecher, C. W.; Fong, H. H.; Kinghorn, A. D.; Brown, D. M.; et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med. 1995, 1, 1046-1051.
34. Schmidt, M. L.; Kuzmanoff, K. L.; Ling-Indeck, L.; Pezzuto, J. M. Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur. J. Cancer 1997, 33, 2007-2010.
35. Sarek, J.; Klinot, J.; Dzubak, P.; Klinotova, E.; Noskova, V.; Krecek, V.; Korinkova, G.; Thomson, J. O.; Janost'akova, A.; Wang, S.; Parsons, S.; Fischer, P. M.; Zhelev, N. Z.; Hajduch, M. New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships. J. Med. Chem. 2003, 46, 5402-5415.
36. Kim, J. Y.; Koo, H. M.; Kim, D. S. Development of C-20 modified betulinic acid derivatives as antitumor agents. Bioorg. Med. Chem. Lett. 2001, 11, 2405-2408.
37. You, Y.-J.; Kim, Y.; Nam, N.-H.; Ahn, B.-Z. Synthesis and cytotoxic activity of A-ring modified betulinic acid derivatives. Bioorg. Med. Chem. Lett. 2003, 13, 3137-3140.
38. Fulda, S.; Jeremias, I.; Pietsch, T.; Debatin, K. M. Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors. Klin. Padiatr. 1999, 211, 319-322.
39. Fulda, S.; Jeremias, I.; Steiner, H. H.; Pietsch, T.; Debatin, K. M. Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int. J. Cancer 1999, 82, 435-441.
40. Fulda, S.; Debatin, K.-M. Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia 2005, 7, 162-170.
41. Sawada, N.; Kataoka, K.; Kondo, K.; Arimochi, H.; Fujino, H.; Takahashi, Y.; Miyoshi, T.; Kuwahara, T.; Monden, Y.; Ohnishi, Y. Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br. J. Cancer 2004, 90, 1672-1678.
42. Fulda, S.; Jeremias, I.; Debatin, K.-M. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004, 23, 7611-7620.
43. Shin, Y. G.; Cho, K. H.; Chung, S. M.; Graham, J.; Das Gupta, T. K.; Pezzuto, J. M. Determination of betulinic acid in mouse blood, tumor and tissue homogenates by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 1999, 732, 331-336.
44. Udeani, G. O.; Zhao, G. M.; Geun Shin, Y.; Cooke, B. P.; Graham, J.; Beecher, C. W.; Kinghorn, A. D.; Pezzuto, J. M. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm. Drug Dispos. 1999, 20, 379-383.
45. Smith, P. F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G. P.; Martin, D. E. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 2007, 51, 3574-3581.
46. Martin, D. E.; Blum, R.; Doto, J.; Galbraith, H.; Ballow, C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin. Pharmacokinet. 2007, 46, 589-598.
47. Yasukawa, K.; Takido, M.; Matsumoto, T.; Takeuchi, M.; Nakagawa, S. Sterol and triterpene derivatives from plants inhibit the effects of a tumor promoter, and sitosterol and betulinic acid inhibit tumor formation in mouse skin two-stage carcinogenesis. Oncology 1991, 48, 72-76.
48. Liby, K.; Honda, T.; Williams, C. R.; Risingsong, R.; Royce, D. B.; Suh, N.; Dinkova-Kostova, A. T.; Stephenson, K. K.; Talalay, P.; Sundararajan, C.; Gribble, G. W.; Sporn, M. B. Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Mol. Cancer Ther. 2007, 6, 2113-2119.
49. Rajendran, P.; Jaggi, M.; Singh, M. K.; Mukherjee, R.; Burman, A. C. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest. New Drugs 2008, 26, 25-34.
50. Bi, Y.; Xu, J.; Wu, X.; Ye, W.; Yuan, S.; Zhang, L. Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives. Bioorg. Med. Chem. Lett. 2007, 17, 1475-1478.
51. Saelens, X.; Festjens, N.; Vande Walle, L.; van Gurp, M.; van Loo, G.; Vandenabeele, P. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23, 2861-2874.
52. Walczak, H.; Krammer, P. H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 2000, 256, 58-66.
53. Fulda, S.; Debatin, K.-M. Targeting apoptosis pathways in cancer therapy. Curr. Cancer Drug Targets 2004, 4, 569-576.
54. Degterev, A.; Boyce, M.; Yuan, J. A decade of caspases. Oncogene 2003, 22, 8543-8567.
55. Salvesen, G. S.; Duckett, C. S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3, 401-410.
56. Micheau, O. Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin. Ther. Targets 2003, 7, 559-573.